Idera's TLR antagonist shows psoriasis promise despite missing PhIIa endpoint
This article was originally published in Scrip
Executive Summary
Idera Pharmaceuticals said the results of its Phase IIa clinical trial for IMO-3100, a selective antagonist of toll-like receptors (TLRs) 7 and 9, provide clinical proof-of-concept for selective TLR inhibition in the treatment of psoriasis and possibly for other autoimmune and inflammatory disorders. This is despite the study's missed primary endpoint related to epidermal thickness as assessed by skin biopsies at baseline and at four weeks of treatment.